Discover verified cancer discoveries

Search and filter stories that passed editorial review. Evidence strength, regulatory status, and guideline position are shown separately and are never inferred from one another.

Filter discoveries

Results

Active filters:Clear all

2 verified discoveries match your filters.

Luveltamab tazevibulin showed responses in platinum-resistant ovarian cancer in dose-optimization data; the trial was later terminated

Evidence stage: Emerging ClinicalRegulatory status: Investigational
Cancer type
Ovarian Cancer
Published
August 13, 2026

In the dose-optimization portion of the now-terminated phase 2/3 REFRaME-O1 trial, the antibody-drug conjugate luveltamab tazevibulin produced objective responses in patients with platinum-resistant ovarian cancer expressing folate receptor alpha, at…

Primary source cited

Last reviewed

FDA approves the first immunotherapy regimen for platinum-resistant ovarian cancer with a proven survival benefit

Evidence stage: Later-Stage HumanRegulatory status: FDA Approved
Cancer type
Ovarian Cancer
Published
August 13, 2026

In the randomized, phase 3 ENGOT-ov65/KEYNOTE-B96 trial, adding pembrolizumab to paclitaxel chemotherapy significantly improved BOTH progression-free survival (8.3 vs 7.2 months) AND overall survival (18.2 vs 14.0 months) in patients…

Primary source cited

Last reviewed